Lawrence Silverman
Pediatric Endocrinology · Morristown, NJNPI 1336113653
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $313,690 of the $491,768 with a category attached, or 63.8%. 31 manufacturers reported payments, led by OPKO Pharmaceuticals, LLC at 46.5% of the total. Among pediatric endocrinology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $1707.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$229K
- Pfizer$132K
- Biomarin Pharmaceutical Inc.$55K
- Novo Nordisk$21K
- Tolmar Pharmaceuticals, Inc.$16K
- Tolmar, Inc.$15K
- plus $25K from 25 others
Across 1,177 payments — averaging $391.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$266K
- Ascendis Pharma Endocrinology Inc$55K
- Pfizer$46K
- Biomarin Pharmaceutical Inc.$35K
- Tolmar, Inc.$31K
- Novo Nordisk Health Care AG$27K
What the payments were for
- Consulting fees$313,69064%
- Speaking & faculty fees$137,09328%
- Travel & lodging$33,7627%
- Food & beverage$6,9321%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 20 | $228,705 |
| Pfizer(2 entities) | 69 | $131,771 |
| Biomarin Pharmaceutical Inc. | 44 | $54,732 |
| Novo Nordisk | 40 | $21,187 |
| Tolmar Pharmaceuticals, Inc. | 22 | $16,055 |
| Tolmar, Inc. | 15 | $14,684 |
| Endo Pharmaceuticals Inc. | 9 | $7,208 |
| Ascendis Pharma Endocrinology Inc | 14 | $6,553 |
| AbbVie | 5 | $3,935 |
| Ferring Pharmaceuticals Inc. | 8 | $2,861 |
| Vistapharm, Inc. | 1 | $1,800 |
| Novo Nordisk AS | 4 | $1,370 |
| Sanofi-aventis U.S. LLC | 4 | $269 |
| Medtronic(2 entities) | 8 | $159 |
| Dexcom, Inc. | 4 | $75 |
| Johnson & Johnson | 2 | $59 |
| Insulet Corporation | 3 | $58 |
| Abbott | 3 | $51 |
| Soleno Therapeutics, Inc. | 1 | $25 |
| AstraZeneca | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Lifescan, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENLA$89,666
- Rayaldee$49,218
- GENOTROPIN$35,812
- VOXZOGO 1.2mg$34,271
- FENSOLVI$26,932
- Norditropin$16,016
- SUPPRELIN$7,133
- SKYTROFA$6,252
- Sogroya$4,220
- ELIGARD$3,413
- ZOMACTON$2,558
- Thyquidity$1,800
- Lupron Depot$1,225
- TZIELD$109
How this compares
$491,768 in reported general payments places this provider in the 95th percentile of 59 pediatric endocrinology providers in New Jersey.
Other pediatric endocrinology in Morristown
- Barbara CerameMorristown$5K
- Kanika ShankerMorristown$3K
- Daisy ChinMorristown$1K
- Mansi KanhereMorristown$791
- Melissa WooMorristown$781
- Aditi KhokharMorristown$543
- Harold StarkmanMorristown$263
- Tejal PatelMorristown$146
- Ahmed KhattabNew Brunswick$70K
- Ian MarshallNew Brunswick$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.